Engineered T Cell Engagers for Precision, Depth, and Safety
Artemia's platform leverages high-affinity binding and tuned kinetics to overcome the limitations of first-generation engagers. By optimizing the therapeutic window, we enable potent immune cell activation while minimizing off-target toxicity.
Core Design Principles
Our platform is designed to translate the clinical promise of cellular therapies into scalable, off-the-shelf immunotherapies for outpatient use
Tuned CD3 Engagment
Optimizes T cell activation kinetics
Expands therapeutic window
Deep Immune Cell Depletion
(Autoimmunity)
Targets multiple immune cell subsets
Enables deep immune reset
Multi-Antigen Targeting
(Oncology)
Engagement of multiple tumor antigens
Mitigates tumor escape
From Design to Therapeutic Impact
Translating clinical promise into scalable immunotherapies
Deeper Immune Reset
More complete elimination of disease-driving cells.
Improved Safety Window
Controlled T cell activation reduces toxicity risk.
Durable Responses
Sustained efficacy across autoimmune and oncology settings.
Scalable Delivery Model
Cost-effective, off-the-shelf biologics for outpatient use.